Skip to search formSkip to main contentSkip to account menu

MK 5108

Known as: MK-5108, MK5108 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells
Liposarcoma is a malignant soft tissue tumor that originates from adipose tissue and is one of the most frequently diagnosed soft… 
2014
2014
Long Residence Times Revealed by Aurora A Kinase‐Targeting Fluorescent Probes Derived from Inhibitors MLN8237 and VX‐689
We report the development of three fluorescent probes for protein kinase Aurora A that are derived from the well‐known inhibitors… 
2013
2013
Targeting GD 2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells
2010
2010
A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.
e13026 Background: MK-5108 is a potent, highly selective Aurora A kinase inhibitor. Aurora A is a serine/threonine kinase that… 
2009
2009
Combination Therapy with the Histone Deacetylase Inhibitor Vorinostat Plus the Novel Aurora Kinase A Inhibitor MK-5108 Leads to Enhanced Lymphoma Cell Death Due to Acetylation of p53 and Repression…
Abstract 1690 Poster Board I-716 Background Patients with relapsed or refractory Hodgkin (HL) and Non Hodgkin Lymphoma (NHL) have… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)